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Abstract
Background: Cancerous state is a highly stimulated environment of metabolically active cells. The cells under these
conditions over express selective receptors for assimilation of factors essential for growth and transformation. Such
receptors would serve as potential targets for the specific ligand mediated transport of pharmaceutically active molecules.
The present study demonstrates the specificity and efficacy of protein nanoparticle of apotransferrin for targeted delivery of
doxorubicin.
Methodology/Principal Findings: Apotransferrin nanoparticles were developed by sol-oil chemistry. A comparative analysis
of efficiency of drug delivery in conjugated and non-conjugated forms of doxorubicin to apotransferrin nanoparticle is
presented. The spherical shaped apotransferrin nanoparticles (nano) have diameters of 25–50 gm, which increase to 60–
80 gm upon direct loading of drug (direct-nano), and showed further increase in dimension (75–95 gm) in conjugated
nanoparticles (conj-nano). The competitive experiments with the transferrin receptor specific antibody showed the entry of
both conj-nano and direct-nano into the cells through transferrin receptor mediated endocytosis. Results of various studies
conducted clearly establish the superiority of the direct-nano over conj-nano viz. (a) localization studies showed complete
release of drug very early, even as early as 30 min after treatment, with the drug localizing in the target organelle (nucleus)
(b) pharmacokinetic studies showed enhanced drug concentrations, in circulation with sustainable half-life (c) the studies
also demonstrated efficient drug delivery, and an enhanced inhibition of proliferation in cancer cells. Tissue distribution
analysis showed intravenous administration of direct nano lead to higher drug localization in liver, and blood as compared
to relatively lesser localization in heart, kidney and spleen. Experiments using rat cancer model confirmed the efficacy of the
formulation in regression of hepatocellular carcinoma with negligible toxicity to kidney and liver.
Conclusions: The present study thus demonstrates that the direct-nano is highly efficacious in delivery of drug in a target
specific manner with lower toxicity to heart, liver and kidney.
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Introduction
Current preferred therapeutics focused on effective approaches
involving radiation therapy, laser therapy, chemotherapy etc.
Although surgical intervention alone or in combination with
chemotherapy is a preferred treatment of solid tumors, chemo-
therapy alone is an easy and viable option, but its use is limited due
to 1) non-specific cellular localization of drug, 2) inefficient drug
release, 3) reduced effective drug concentration due to low
solubility and low stability of drugs [1–3]. Such limitations were
addressed through the development of various targeted delivery
systems involving the conjugation of drug to various biomaterials
such as biodegradable polymers made up of polyethylenimine [4],
PLGA [5], modified liposomes [6–9], peptides and proteins
[10,11]. Recent developments include introduction of nanoparti-
cles consisting of poly (ethyl amine)-b-poly(n-isopropyl acetylated
derivative), nanoparticles of Fe3O4 [12,13], polymeric dendrimers
[14,15], poly hydrogen acylated nanoparticles, core-shell co-
polymer nanoparticles [16–18], DOTA–NHS-ester [19], PEG-
PEL nanoparticles [20]. Though these materials are biocompat-
ible, they lack target-specificity besides their high energy-
demanding for degradation of biomaterial in cells and tissues. In
order to enhance target specificity, many drug-loaded materials
are conjugated or coated by iron binding protein transferrin/
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cells [21–24]. Transferrin receptors are abundantly expressed in
active and rapidly proliferating cells and thus targeting such
proteins enables preferential localization of drugs in those cells.
Cancer cells and tissues over expressing transferrin receptors has
enhanced localization of drug [25], thus widening the scope of
drug action on various types of cancers. The limitation in this
approach of the conjugation of drug to the polymers/metal/
proteins/carbohydrates in the drug delivery systems, is that the
cleavage of conjugated functional group is a rate limiting step [26]
and it is inefficient in drug release. The reaction conditions
required for cleavage of the conjugates may work against the
stability of drug [27], thus reducing the effective concentration of
drug.
Apotransferrin is a stable and abundantly expressed protein that
remains in circulation in blood of human beings and animals.
Apotransferrin, upon binding to ferric ion, forms transferrin,
which binds to transferrin receptor on the cell surface and enters
the cell by receptor-mediated endocytosis [28]. The internalized
transferrin is fused with endosome that followed by the release of
iron into the cells. After release of iron, apotransferrin is recycled
back to the cellular surface, which again participates in the
transport of iron in another cycle [29]. Transferrin is a well-
studied ligand for the tumor targeting [22,30] and gene delivery
[31].
The present study examines and evaluates the efficacy of
apotransferrin as a sole drug carrier and compares its drug delivery
efficacy in respect of the two forms - conjugated (conj-nano) and
direct drug loaded nanoparticles (direct-nano). The results clearly
bring out the significant advantage of direct drug loaded
nanoparticles of apotransferrin in accomplishing an affective and
complete drug delivery into the cells.
Results
Polymorphic properties of the protein nanoparticles
Nanoparticles were prepared as described in the methods. In this
study, nano refer to apotransferrin nanoparticles; direct-nano refers to
the apotransferrin nanoparticles containing doxorubicin without
involving conjugation of the drug. The drug is encapsulated into
the particles during preparation of nanoparticles; conj-nano refers to
the nanoparticles comprised of apotransferrin and doxorubicin
conjugates; apo refers to soluble apotransferrin; direct-sol refers to
soluble mixture of apotransferrin and doxorubicin; conj-sol refers
to soluble conjugates of apotransferrin and doxorubicin.
Analysis of nanoparticles by electron microscopy (SEM)
scanning shows that these nano exhibit a uniform spherical
shapes, dimension with diameters ranging from 20–40 gm
(Figure 1A). Further analysis of nano using atomic force microscopy
(AFM) shows clear particle to particle separations in surface
projections, with diameters ranging from 13 to 30 gm (Figure 1B).
Interestingly, while spherical shape of the particles remained intact
in direct-nano with diameter of 60–80 gm on SEM (Figure 1C),
the particles exhibit significant surface projections of 1–3 gm
diameter (on AFM) (Figure 1D), suggesting clear polymorphic
changes of the direct-nano in the presence of doxorubicin. The
particle diameter (on SEM) increased to 75–95 gm in conj-nano
(Figure 1E) with correspondingly increased surface projections of
15 gm (Figure 1F). In the case of nanoparticles made up of the
albumin alone, particles were of 60–75 gm (Figure 1G). Analysis
on AFM show 12 to 19 gm surface projections (Figure 1H) with
distinctly different polymorphic features compared to those
observed for nano (Figure 1A). These results point out that the
nanoparticles are below 100 gm diameter, and they exhibit
characteristic polymorphic features, which vary with form of the
nanoparticles viz., nano, direct-nano, conj-nano, BSA nano.
Characterization of nanoparticles
The experimental results clearly indicate that protein concen-
tration below 5 mg is not adequate for nano particle formation,
while concentrations above 30 mg protein are found to result in
formation of large sized particles of dimensions 200–400 gm. It
was also found that during sonication, the amplitude below 2 mm
is not adequate for formation of particles. Also, the centrifugation
speed is important for appropriate precipitation of particles. The
particles could not be separated from oil phase at 81 x g. At 324–
1296 x g pellet was formed loosely, while at very high speeds of
3968 x g and above very tight pellet was formed, which was
difficult to disperse. Finally, 2025–2915 x g was found to be an
optimum speed at which the particles could be collected and
dispersed.
The physico-chemical properties of the particles were analyzed
by treating the particles in the presence of solvents of increasing
polarity and estimating the extent of doxorubicin released. If one
assuming that the particles are protected by oil, the particles
should be sensitive and collapse in the presence of low polar
organic solvents leading to release of significant amounts of
doxorubicin. The results of fluorimetry presented in Figure 2A
show that the particles are indeed found to be intact in the
presence of solvents having polarity as low as zero (hexane) and
olive oil miscible solvent pyridine [32], and no significant amount
of doxorubicin is released from particles suggesting that the
particles are not protected by any oil film. Analysis of dried
nanoparticles by solid IR showed no signs of olive oil in the
particles (Figure S1). To further investigate, whether the particles
are made of proteins, the particles were incubated in the presence
of decreasing pH for 6 hours. The results of these studies clearly
demonstrated that the particles are indeed made of protein alone.
Since transferrin binding to receptor is a pH dependent, the ability
of pH dependent release of drug from nanoparticles was studied.
The results presented in figure 2B show that the particles formed
both by direct-nano and conj-nano were sensitive below pH 6,
maximum amount of drug release at pH 5 suggesting that a pH
dependent release of drug can take place from the particles.
Furthermore, the particles were immunoreactive to mouse anti-
human transferrin (Figure 2C) confirming that the particles are
indeed comprised of apotransferrin and the immunological
epitopes of apotransferrin and are found intact for their molecular
activity.
The process of protein drug nanoparticles preparation initially
involves initially adsorption of the drug into the protein in the
presence of oil phase leading to aggregation of drug-protein
complexes. The complexes get disaggregated by sonication. The
disaggregates are cooled in liquid nitrogen or on dry ice to induce
their precipitation. Soluble mixtures of drug and protein, upon
addition to oil phase, induce adsorption of drug to the protein
followed by phase changes that lead to formation of solidified
drug-protein particles. The drug may thus be loaded into cavities
formed by the protein complexes through adsorption. The
efficiency of the drug loading though this mode may be seen
from the concentration of drug encapsulated in protein nanopar-
ticles which is found to be as much as 500 mg in 1 mg of
apotransferrin protein (50% loading). The dimension of nanopar-
ticles loaded with drug directly is 60–80 gm (Figure 1E), while
conjugated nanoparticles show dimension of 80–100 gm
(Figure 1G). This methodology has been successfully employed
in the present study to prepare apotransferrin nanoparticles of a
Protein Nano Drug Delivery
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7240Figure 1. Microscopic Analysis of Nanoparticles: Apotransferrin nanoparticles were prepared as described in methods. The particles were
analyzed by SEM, and AFM. Panel A depicts SEM image of nano. SEM image of direct-doxo were given in panel C. Panel E show the SEM image of
conj-nano. Panel G show the SEM image of BSA nano. Panel B, D, F, H illustrates surface morphology of nanoparticles using AFM. Several independent
experiments were carried out. The quality of nanoparticles used in each experiment reported in manuscript was confirmed by SEM analysis.
doi:10.1371/journal.pone.0007240.g001
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oxaliplatin, etoposide etc (data not shown).
Furthermore, surface display analysis of apotransferrin nano-
particles (Figure 1B, D, F, H), shows significant surface projections
indicating that the epitopic and structural projections of protein on
the surface of the nanoparticles may be retained. This is also
further confirmed by the intact immuno-reactivity of protein in
nanoparticles with mouse-anti-human apotransferrin monoclonal
antibody, as observed through western blotting (Figure 2C).
Mechanism of apotransferrin nanoparticles mediated
drug delivery
The efficiency of delivery of doxorubicin into cells in both cases
i.e., conj-nano and direct-nano, was monitored using FITC-
conjugated nanoparticles. Different forms of nanoparticles were
added to Sup-T1 cells and incubated for indicated time points.
The amount of FITC-conjugated apotransferrin was monitored by
fluorimetry (l Ex 495 gm and Em 521 gm). The results presented
in Figure 3A, show that in the case of the direct-nano treated cells,
the doxorubicin present is at higher concentrations in the cells in a
time dependent manner compared to conj-nano, suggesting an
efficient drug entry through apotransferrin in direct-nano as
compared to that observed in conj-nano. Furthermore, nanopar-
ticles mediated drug entry is found to be more efficient compared
to that of soluble apotransferrin (Figure 3A).
The specificity of apotransferrin nanoparticles in cellular
interaction and entry was assessed by competition of nanoparticles
binding in both the presence and absence of mouse anti-human
transferrin receptor monoclonal antibody (1 mg/0.5 million cells).
The results show that transferrin receptor specific antibody
significantly inhibited the endocytosis of both direct-nano and
conj-nano (Figure 3A). This suggests that the drug delivery by
apotransferrin nanoparticles is mediated specifically through
transferrin receptor mediated endocytosis.
We have also conducted experiments wherein doxorubicin
loaded nanoparticles (both direct-nano & conj-nano) were added
to Sup-T1 cells, to examine if the transferrin nanoparticles follow
the same natural iron transport pathway. The amount of
apotransferrin localized in the cells was monitored by quantifica-
tion of FITC fluorescence (Ex: 495 gm, Em: 521 gm) using
fluorimetry. Same cells were also monitored for doxorubicin (Ex:
470 gm, Em: 595 gm). The results of this study shown in
(Figure 3B and C), show that direct-nano has its highest
apotranferrin entry at 2 hrs after the addition of nanoparticles
(Figure 3B), while the drug release maximum at 4 hrs after
addition, followed by more than 50% secretion of protein by the
cells within 48 hrs (Figure 3B). On the other hand, the apo-sol,
doxo-sol and conj-nano showed lesser protein re-cycling and low
drug release rate suggesting that conjugated form follows the
localization mechanism similar to that of soluble apotransferrin.
The recycling of apotransferrin observed in the targeting of
doxorubicin in cancer cells was further examined and confirmed
by analysis of the localization of doxorubicin and FITC-
conjugated apotransferrin in nanoparticles in Sup-T1 cells by
confocal microscopy. Incubation of nanoparticles for 30 min in
the case of conj-nano showed the presence of doxorubicin in
cytosol, possibly associated with endosomes, which released drug
at 2 hours post incubation. This suggests that the drug-protein
conjugates follow a mechanism similar to that of iron release
through endosomes (Figure 4). In contrast, doxorubicin in direct-
nano, was found localized in the nucleus (Figure 4), and was found
to be stable throughout the 4 hours period of post incubation,
pointing out that direct-nano can efficiently and completely
localize drug in cells.
Antiproliferative activity of apotransferrin nanoparticles
Doxorubicin apotransferrin loaded nanoparticle forms (conju-
gated and nonconjugated) were tested for bioactivity in terms of
anti-proliferative activity of doxorubicin against three different
cancer cell lines SupT1, Colo-205 and SK-N-SH and PHA
stimulated PBMC’s, using MTT assay. The results (Figure 5) show
that apotransferrin directly loaded nanoparticles (nonconjugated)
have significantly inhibited proliferation of cells in the case of all
the four types,, thus suggesting that this delivery method is free
Figure 2. Physicochemical characterization of nanoparticles.
Panel A. Surface property of nanoparticles: Sensitivity of conj-
nano and direct-nano (200 mg protein equivalent) in solvents of
increasing polarity (X-axis) was monitored by incubating in the
presence of indicated solvent for 30 min at room temperature and
doxorubicin released was measured by fluorimetry (at lEx 470 nm
lEm595 nm) was plotted on Y axis. Panel B. pH dependent release
of doxorubicin from nanoparticles: Direct-nano (200 mg protein
equivalent) was incubated in the presence of buffers at indicated pH (X-
axis) for 30 min and the amount of doxorubicin released was measured
by fluorimetry (at lEx 470 nm lEm595 nm) for 30 min at room
temperature. Data is represented as an average of three determinations
with standard deviation. Panel C: Analysis for Apotransferrin
protein in the Nanoparticles: Nanoparticles were denatured and
separated on 10% SDS PAGE and western blot analysis was performed
as described in methods. (1) BSA (–ve control) (2) Apo-sol (+ve Control)
(3) 50 mg direct-nano (4) 100 mg direct-nano (5) 50 mg conj-nano (6)
100 mg conj-nano).
doi:10.1371/journal.pone.0007240.g002
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exhibits relatively low activity compared to direct-nano with
statistically significant differences between BSA-nano and Direct-
nano at 10 mg( p ,.005) and 100 mg( p ,.002) of doxorubicin from
Holm-Sidak pair-wise multiple comparison procedures, suggesting
the importance of receptor mediated endocytosis in the case of
apotransferrin.
In summary, the results of the study show a clear advantage of
direct-nano in terms of rapid and complete localization of drug in
the target organelle, nucleus, thus conferring potent anti-
proliferative activity to the drug. This provides thus providing an
efficient delivery of the drug in the case of all the four cell types
examined and facilitates an effective inhibition of proliferation.
Pharmacokinetic studies of drug release kinetics with the
nanoparticles
Nanoparticles and drug conjugates viz., direct-nano, Conj-
nano, direct-sol, were administered to rats through intra peritoneal
route. Drug localization in blood (Figure 6B) as well as liver
(Figure 6C) was monitored. The drug in blood and in liver was
extracted and estimated by HPLC analysis at 4 hrs, 8 hrs and
16 hrs post administration. Results of the HPLC analysis of pure
doxorubicin and the doxorubicin isolated from blood, shown in
Figure 6A clearly bring out the efficiency of the method.
Direct-nano administration did show significant drug localiza-
tion in blood right from the time points 4 hrs post-administration
onwards. On the other hand, the conj-nano and soluble forms
showed only very low concentrations of doxorubicin at 4 hrs post
administration. Further, in direct-nano administered rats, higher
concentrations were detected in circulation in blood at 8 hours of
post-administrations that remained stable for 16 hours. In
contrast, in the case of direct-sol and conj-nano administration
negligible concentrations were present at 4 hours, with levels of
concentrations of doxorubicin detected becoming significant only
after 8 hours of post administration that reaches maximum at
16 hours of post-administration. This suggests the doxorubicin in
direct-nano is rapidly and completely released in circulation and
remained stable, while the release of drug in the case of conj-nano
and direct-sol is relatively slow and incomplete. Similar results
have been obtained in the case of localization of drug in liver.
These results clearly demonstrate that the intra peritoneal
administration of direct-nano formulation of drug in rat is efficient
in release of drug in circulation compared to other forms.
Tissue localization of doxorubicin, when direct-nano and
conj-nano were administered through intravenous route
in rats
The localization of the doxorubicin, when administered
through intravenous route was assessed by the administration of
direct-nano and conj-nano followed by surgical removal of the
organs viz. brain, liver, heart kidney, spleen and bone marrow.
The doxorubicin was extracted from the tissue as per methods
and estimated by fluorimetry. The results presented in Figure 7
show that the levels of doxorubicine were higher in heart, when
soluble doxorubicin is administered compared that with direct-
nano. Further, the doxorubicin shown to be localized higher
levels in liver in direct-nano treated rat compared to conj-nano
and doxo alone. Following liver, the drug localization was
significant in kidney and in circulation in blood. Lowest drug
concentrations havebeendetected inheart, brainand spleenthus
reducing the risk of direct-nano other non-target organs. Since
administration of doxorubicin alone is known to exhibit cardio
toxicity, the current methodof delivery usingdirect-nanoreduces
Figure 3. Mechanism of apotransferrin nanoparticle mediated
drug delivery. Panel A. Specificity of nanopraticle interaction
with transferrin receptor: SupT1 cells were incubated with indicated
FITC-conjugated transferrin nanoparticles in presence or absence of
mouse anti-human transferrin receptor MAb. After indicated time
intervals, cells were lysed and centrifuged at 11,661 x g for 20 min at
4uC. Supernatants were collected and FITC-apotransferrin was quanti-
fied at 490/520 gm (Ex/Em). Each data point is a mean of 3
independent determinations, the mean and standard deviation is
shown with error graph. Panels B & C. Quantitative cellular
localization of apotransferrin and doxorubicin: 100 mg apo-nano
were added to Sup T1 cells (1 million) and incubated at different time
points as indicated in figure. Cells were harvested and washed thrice
with PBS and lysed in lysis buffer. Lysate was centrifuged at 11,661 x g
for 20 min and supernatant was used for the quantification of FITC-
apotransferrin and doxorubicin. Panel B: apotransferrin recycling in
cells. Panel C: Doxorubicin loading in cells. Each data point is a mean
of 3 independent determinations, the mean and standard deviation is
shown with error graph.
doi:10.1371/journal.pone.0007240.g003
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advantage of reducing the rise of the doxorubicin related-cardio
toxicity.
Efficacy of apotransferrin drug nanoparticles in
regression of ascetic liver carcinoma in rats
Ascetic liver hepatocellular carcinoma is induced in rat by
administration of 0.2 million of ZH5 cells through intra peritoneal
route. In this model, the rat develops a full-blown cancer by day 4
and survives only for 7 days. The nanoparticle formulation of drug
is administered as it has been shown from the pharmacokinetic
studies, the drug is significantly released both circulation and liver
through this mode (Figure 6). Even the intravenous administration
of nanoformulation indeed showed significant levels of drug
localization in liver (Figure 7).
Treatment of hepatocellular carcinoma injected rats, using the
direct-nano delivery method, showed very significant regression in
cancer with survivability of 150 days for 4 rats in a group of 6 rats.
The statistical significance of cancer regression in groups was
analyzed by ANOVA analysis and Tukey’s Honestly significant
difference (HSD) test. The results presented in Table 1 showed
that differences of means among the groups are significant with
probability of above 95%.
A group of 6 rats were induced cancer and indicated agent
(Table 1) was administered intra peritoneal from day-1 of post-
induction for a period of 6-days and rats were sacrificed at day-6
and the relevant parameters were estimated in liver, kidney and
urine. The results presented in Table-1 clearly bring out that
direct-nano treated rats showed a significant regression of tumor.
Further, the results of toxicity to liver and kidney in the case of
Figure 4. Localization of apotransferrin and doxorubicin in Sup-T1 cells. 100 mg apo-nano containing of protein-drug (conjugated as well
as direct) were added to the cells (1 million) and incubated at different time points as indicated in figure. Cells were harvested at 30 min, 1 hour,
2 hours and 4 hours, then washed thrice with PBS and re-suspended in PBS. Cells were viewed in Leica confocal microscope, green fluorescence is
due to the FITC-conjugated Apotranferrin and red fluorescence is due to intrinsic fluorescence of doxorubicin.
doi:10.1371/journal.pone.0007240.g004
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while treatment with soluble doxorubicin and direct-sol show low
survival rates compared to direct-nano (Table 1). These results
suggest that soluble forms of doxorubicin in the presence and
absence of apotransferrin has no significant advantage. BSA-nano
did not show significant regression of cancer as per Tukey’s HSD
pair-wise comparison analysis between BSA nano and direct-nano
treated rats, thus suggesting the importance of receptor recogni-
tion in transferrin-mediated endocytosis of direct-nano in specific.
In general, target specificity would determine the site of drug
delivery through protein nanoparticles in vivo.
Since serum alkaline phosphate plays a significant role in tissue
and cellular damage in liver, it serves as an important indicator
for assessing the cancer-induced liver toxicity in hepato-
cellular carcinoma progression. The results of analysis of alkaline
phosphatase in nanoparticle treated rat amounts to
60.4960.81 IU/L, which comes close to that for healthy ones,
57.0260.04 IU/L (Tukey HSD difference 3.47610.43 between
healthy and direct-nano nanoparticle treated). The treatment
through direct-nano nanoparticles can thus have the advantage of
inhibiting cell and tissue damage in liver. The enzyme level is four
fold higher in untreated rat (252.0161.36 IU/L with Tukey HSD
difference is 191.51610.43).
The direct-nano nanoparticles treated rats have also shown
significant decrease in the levels of the prognostic hepatoma
marker serum, lactate dehydrogenase (LDH). While it was
20664 IU in untreated rats (Tukey HSD difference is
154.8610.76), it has decreased to, 51.6861 IU/L, a value close
to that of healthy rats (Table 1). To monitor, metabolic disorder, if
any, caused upon induction of hepatocellular carcinoma, serum
creatinine and urea were estimated in rats. The creatinine in
treated rats remained the same as that for healthy as well as direct-
nano drug treated rat (Tukey HSD difference less than 0.04). The
serum urea in untreated rats increased significantly by 5 fold
(Tukey HSD difference 21.4361.92), while it remained low in
healthy and direct-drug nanoparticle treated rats (Table-1)
suggesting that treatment did not induce any toxicity to kidney.
The observed decrease of efficacy of doxorubicin in BSA
nanoparticles could be due to their inability in cellular binding
and release of doxorubicin (Table 1). This indicates that receptor
recognition and binding of apotransferrin nanoparticles play an
important role in drug release. The results thus show that direct-
drug nanoparticles can significantly and efficiently regress cancer
in rat hepatocellular carcinoma and this is further confirmed by
their longer survival rate (Table 1) and immunohistochemistry
(Figure S2).
Figure 5. Antiproliferative activity of apotransferrin nanoparticles mediated drug Delivery. SUP-T1, Colo 205, SK-N-SH and PBMC’s were
incubated for 16 hours in the presence of increasing concentrations of indicated test sample. The quantity of viable cells was estimated by MTT assay.
The MTT O.D value for control in absence of any test sample was taken as 100% viable. The viability of cells in each test sample was computed with
reference to this value. Each data point is a mean of 3 independent determinations, the mean and standard deviation is shown with error graph.
doi:10.1371/journal.pone.0007240.g005
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Cells express two types of Transferrin receptors,TfR1 and
TFR2, TfR1 is expressed on all nucleated cells including
hepatocytes, but with differences in level of expression [33].
Altered iron metabolism is shown to favor TfR1 and is over
expressed in Hepatocellular carcinoma (HCC) in rats [34] and in
tumors of human HCC patients [35–37]. Since HCC is
diagnostically frequently detected at advanced stage and short
time is available for intervention, the current research efforts are
focused mainly on the development of carriers to allow a rapid and
efficient delivery of drug, which is an immediate need for
treatment of HCC. Emerging cancer therapies involve use of
conjugated drug delivery systems with polymeric materials,
proteins, carbohydrates and other biodegradable materials [38].
The present study aimed at developing a new approach for
targeted delivery of drugs to cancer in general and HCC in
particular, investigates the efficacy of doxorubicin direct-nano in
treatment of hepatocellular carcinoma based on a rat cancer
model through a localized administration by intra peritoneal route.
The results showed that the apotransferrin nanoparticles of
dimensions 30–50 gm, can efficiently and quantitatively load the
drug and when loaded they assume a dimension of 60–80 gmi n
the case of doxorubicin.
Further, the particle size is inferred to be dependent on the
globular nature of the protein as BSA nano particles (globular)
showed higher dimensions compared to direct-nano made of
apotransferrin. The surface properties of the nanoparticles depend
on the form of the protein species present, that is, whether it is in
conjugated or non-conjugated form. The doxorubicin in both
direct-nano and conj-nano modes is shown localized into cells
through transferrin receptor mediated endocytosis, with a
relatively higher concentration of drug delivery by the direct-
nano. This in turn is succeeded by secretion of the apotransferrin
protein from the cell facilitating removal of the delivery vehicle
apotransferrin from the cell, thus reducing burden to the cell from
delivery vehicle. The direct-nano mode is found to be highly
efficient in delivery of drug through intra-peritoneal route, as
significant amount of drug was observed in circulation at 4 hrs
of post administration, reaching a maximum at 8 hrs and
Figure 6. Pharmacokinetics analysis of nanoparticle based delivery of doxorubicin in rats. Rats were administered through intra-
peritoneal route with direct-nano and conj-nano. Blood and liver were collected at indicated time points and processed as mentioned in the
methods. Panel A: HPLC analysis of doxorubicin i) 100 gg pure doxorubicin in methanol, ii) 100 gg doxorubicin suspended in rat blood and
extracted and subjected to HPLC, iii) 50 ng doxorubicin suspended in rat blood and extracted and subjected to HPLC. Panel B: HPLC analysis of
indicted forms of doxorubicin extracted from rat blood indicated time after administration: i) soluble doxorubicin sol, ii) direct-nano, iii) conj-nano.
Panel C: HPLC analysis of indicted forms of doxorubicin from liver after indicated intra peritoneal administration. Liver extract was prepared and
doxorubicin was quantified through HPLC. i) soluble doxorubicin, ii) direct-nano, iii) conj-nano.
doi:10.1371/journal.pone.0007240.g006
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and doxo-sol, which showed low concentrations of drug release.
The anticancer activity of direct-nano was also found to be
significantly high on different cell lines tested. Also, the
intravenous administration is found to be efficient in delivery of
drug to liver suggesting that this may be considered as a possible
route of application of this formulation in human studies as well
for treatment of HCC or any liver cancer in future.
Doxorubicin is known to cause cardio toxicity [39], but tissue
distribution studies through intravenous administration of direct-
nano and conj-nano, showed that the highest localization of the
doxorubicin occurred in liver and kidney compared to other
organs especially lower levels are found in the heart. Further, the
level of doxorubicin in heart decreased with time in case of direct-
nano, in contrast to an increase with time in the case of soluble
doxorubicin. Due to such lower drug localization in heart, the
direct- nano delivery method reduces the risk of doxorubicin
related cardio toxicity.
The mechanisms of transportation of drug into tumors from the
bloodstream are yet to be fully understood [40]. The nanoparticle
uptake of the organs like liver and spleen is mainly based on their
surface characteristics [41]. Particles with more hydrophobic
surfaces are preferentially taken up by the liver, followed by the
spleen and lungs [42]. Hydrophilic nanoparticles (35 gm diam-
eter), such as those prepared from poly(vinyl pyrrolidone), show
less than 1% uptake by the spleen and liver and show as much as
5–10% of particles still circulating in the bloodstream even at 8 hrs
after injection. This study shows that significant concentrations of
drug is localized in liver, blood and kidney (Fig. 6 &7), while
protecting the HCC bearing animals from cancer-induced toxicity
to both liver and kidney (Table 1). However, nanoparticles
composed of 50% PNVP and 50% n-isopropyl acrylamide (45 or
126 gm diameter) also showed preferential uptake by the liver
[43,44]. It has been shown that coatings of hydrophilic polymers
can create a cloud of chains at the particle surface which will repel
plasma proteins, may be involved in specific cellular localization
[45]. Other routes include formulations of the particles from
branched or block copolymers with hydrophilic and hydrophobic
domains [46]. The heterogeneity of blood flow in non-necrotic
regions of tumors is highly relevant and any addition of even
slower and unpredictable blood flow in necrotic and semi-necrotic
regions only compounds the complexity of the challenging task of
drug delivery to cancerous tissues. In this context, the apotrans-
ferrin drug delivery system presented here will form a new class of
drug delivery systems originated from a natural cellular transport
pathway without involving any conjugation to the drug. Further,
this is a new low-toxic approach for fast and complete drug
delivery, as compared to some of the conjugated drug delivery
systems. This technology can be applied to any protein ligand that
has a specific receptor on the target cell. Furthermore, the use of
allogenic protein from the same patient will prevent the rare
immuno-rejection of the delivery vehicle.
Materials and Methods
Materials
Apotransferrin was purified from human blood following the
method of Cohn et al. [47]. Doxorubicin was a pharmaceutical
preparation of Biochem Pharmaceutical Industries, Pune, India.
SUP-T1 cells were from NIH-AIDS reference and reagents
program, USA. SK-N-SH, COLO-205 cells were from NCCS
Pune, India. PBMC’s were isolated as described in [48]; All other
reagents and biochemicals were of analytical and molecular
biological grade.
Animals
All animal experiments were conducted as per approval of the
Institutional Animal Ethics Committee (IAEC) of the University of
Hyderabad. Wister rats (Age: 6–8months, Weight: 0.15–0.175 kg)
Figure 7. Localization of protein and doxorubicin through
intravenous administration. Rats were intravenously administered
RITC-labeled apotransferrin nanoparticles, direct-nano, conj-nano.
Organs as indicated were surgically collected and RITC-apotransferrin
and doxorubicin were extracted from tissue homogenate as per the
procedure given in ‘‘experimental section’’. Amount of RITC was
estimated by fluorimetry at 573 nm (lem), while amount of doxorubicin
was estimated at 585 nm (lem). Each data point is an average of 3
independent experiments with standard deviation is shown as error.
doi:10.1371/journal.pone.0007240.g007
Table 1. Efficacy of nanoparticle delivery system in regression of hepatocellular carcinoma in rats.
Parameters Average (SD) Untreated Direct-nano* Direct- sol* Doxo sol* BSA nano* Saline/healthy rats*
Serum Lactate Dehydrogenase (IU/L) 206.48 (4.01) 51.68 (1.03) 89.89 (0.84) 90.19 (1.10) 182.04 (3.34) 51 (0.73)
Serum Alkaline Phosphatase (IU/L) 252.01 (1.36) 60.49 (0.81) 71.33 (0.52) 123.97 (4.09) 184.86 (3.05) 57.02 (0.04)
Serum Creatinine (mg/dl) 0.23 (0.01) 0.19 (0.02) 0.2060.01 0.20 (0.01) 0.2060.006 0.21 (0.01)
Serum Urea (mg/dl) 26.05 (0.86) 4.66 (0.04) 3.63 (0.007) 4.58 (0.007) 19.21 (0.53) 4.62 (0.13)
Survival time (days) 7 (1) No sign of death 16 (1) 16 (1) 8 (1) No sign of death
SD: Standard deviation; Doxo: Doxorubicin. Each group has 6 animals. (*) 10 days treatment. Differences between the groups were analyzed by ANOVA. Tukey’s HSD test
was carried out for pair wise comparison of mean values of each group. Data is presented in supporting data.
doi:10.1371/journal.pone.0007240.t001
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nanoparticles loaded drugs were injected through intra peritoneal
and intravenous routes. After indicated time points, blood, liver,
kidney, heart, spleen, brain and other organs were collected as per
the approval of the IAEC and drug was extracted by silver nitrate
and methanol method.
Nanoparticle (Direct nano) Preparation
For preparation of nanoparticles, procedure described in
Kondapi et al., [49] was adopted. 25 mg of apotransferrin
dissolved in 100 ml of phosphate buffer saline (PBS) or dimethyl
sulphoxide (DMSO). The solution of apotransferrin (100 ml) was
slowly mixed with a 100 mM of doxorubicin hydrochloride
(3.46 mg in 100 ml DMSO) and the mixture was incubated on
ice for 5 min. The mixture of apotransferrin and the drug was
slowly added to 30 ml of olive oil at 4uC with continuous
dispersion by gentle vortexing. The sample was sonicated at 4uC
using an MSE sonicator probe (PG43301, MSE Instruments, UK)
or equivalent with a 30 sec period pulse, having an amplitude of
5 mm. This sonication step was repeated 15 times with a gap of 1
minute between successive steps. The resulting mixture was
immediately frozen in liquid nitrogen for 10 min. and was then
transferred to ice and incubated for 4 hours. The particles formed
were pelleted by centrifugation at 2915 x g for 10 min at 4uC and
the pellet was extensively washed with diethyl ether and dispersed
in phosphate buffered saline (PBS). The particles were then
estimated for protein using Biuret method and the nanoparticles
were expressed in terms of protein concentration equivalents. The
possibility of protein or doxorubicin entrapment in the form of
emulsion along with the nanoparticles was assessed through the
study of solubilization of the final pellet for water or DMSO
soluble doxorubicin by fluorimetry and apotransferrin by Biuret
method. No significant soluble forms of doxorubicin or apotrans-
ferrin were found thus ruling out the possibility of any emulsion
formation during the particle preparation. Nanoparticles in pellet
form were stable. When dispersed in PBS they were stable for 1
week at room temperature and for 2 months at 4uC and 6 months
at 280uC.
Optimization of the nanoparticle preparation
Direct nanoparticles were prepared as described in ‘‘Direct-
nano’’ under varying conditions of sonication, centrifugation, and
protein concentration and aqueous to oil ratio. The particles were
washed extensively with ether and dispersed in PBS followed by
the analysis of particles using SEM.
BSA nanoparticles
BSA nanoparticles were prepared as described in ‘‘direct nano’’
preparation (as explained above) using 25 mg of albumin from
bovine serum (Sigma chemical co.) in place of apotransferrin.
Fluorescence/rodamine isothiocyanate (FITC/RITC)
Conjugation of apotransferrin
Apotransferrin was conjugated with FITC/RITC as described
in product manual of Sigma Chemical Co.. FITC/RITC-
conjugated apotransferrin was used directly for the preparation
of nanoparticles.
Doxorubicin conjugation with apotransferrin
Doxorubicin was conjugated with apotransferrin by coupling
with EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hy-
drochloride). 10 mg of purified apotransferrin in ultrapure water
was mixed with 3.46 mg (100 mM) of doxorubicin and 10 mg of
EDC. The contents were mixed thoroughly and reaction was
carried out for 2 hrs at room temperature. Non-conjugated drug
was removed by dialysis (membrane with 12 KDa cut–off) against
PBS. Buffer was changed 4 times with a 6 hr time interval. The
conjugated protein, after dialysis, was used for experiments and for
preparation of conjugated nanoparticles.
Characterization of Nanoparticles
Structure and morphology of the nanoparticles were investigated
using Scanning electron microscope (Philips FEI-XL 30 ESEM,
USA - operated at 20 kV), Transmission electron microscope
(JOEL JEM 1011, USA - operated at 100 kV), and Atomic force
microscope (SPA-400, USA); manufacturers’ instructions were
followed for sample preparation, data collection, and analysis of
particles as describe below.
Transmission electron microscopy (TEM) [50]
Unstained samples of a apotransferrin drug loaded/unloaded
nanoparticles were prepared for electron microscopy measure-
ments/observations, by air-drying small drops of a sample solution
onto carbon-coated copper electron microscopy grids, to obtain
stained images of protein nanoparticles, the electron microscopy
grids containing air-dried samples were incubated with a 2% (w/v)
aqueous uranyl acetate solution for 10 min at room temperature
and washed 3–4 times with distilled water. Protein nanoparticle
images were examined using the JOEL JEM 1011 100 kV electron
microscope. Electron diffraction patterns were recorded from a
selected area that is well occupied with protein nanoparticles in
order to obtain high diffraction intensities. Particle size distribu-
tions were made by measuring diameters for 50 protein
nanoparticles.
Scanning Electron Microscopy [51]
Nano particle samples were analyzed using a PHILIPS FEI-XL
ESEM (USA), operated at 100 kv). Metal stubs were coated with
double-sided adhesive tape and nanoparticles were dispersed on
the sticky surface. Specimen was air dried in dust free environment
at room temperature for one hour, then coated with gold in
Sputter Coater. Specimens were stored in dry, dust free
environment during the analysis. Images were recorded using
appropriate resolution.
Atomic force microscopy [52]
Glass piece (0.560.5 mm) is placed on to one side of a double
stick tape and on to the other side of the tape a mica sheet is
attached. The mica sheet with a cellophane tape stuck on it is
pulled out to peel it and removal of layer of mica sheet was
repeated till several times to obtain a smooth surface of mica sheet.
A5ml of the sample was uniformly dispersed using a spin coater
and dried in a dust free zone for 12 hours. The unit containing the
sample is kept in SPA-400 and images were recorded at different
resolutions and surface morphology was analyzed following
manufacturer’s instructions.
Western blot analysis
50–100 mg of protein equivalent nanoparticles were denatured
by heating at 65uC in the presence of SDS loading buffer and
separated on 7.5% sodium dodecyl sulphate (SDS) gel and then
transferred to nitrocellulose membrane. Western blotting was
carried out as described in Pierce for Western Blot Chemilumi-
nescence Reagent [53]. The blot was developed using mouse anti-
human transferrin Mab (Abcam). The relative levels of protein in
different lanes were compared by analyzing scanned images using
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minimum of three times using independent cultures.
Competition of the transferrin receptor antibodies with
the Apotransferrin-drug Nanoparticles
One million cells were incubated in serum free media for 30 min in
a 12 well plate. FITC labeled Apotransferrin-drug nanoparticles
(equivalent to 50 mg of protein) were added to Sup-T1 cells in the
presence as well as absence of mouse anti-human transferrin receptor
antibody (Calbiochem, 2 mg/million of cells) and incubated for
different intervals of time ranging from 1–8 hrs. After incubation, the
cells were washedthrice withPBS andlysedin1 mlof lysisbuffer. The
lysate was cleared by centrifugation at 11,661 x g for 20 min at 4uC.
Fluorescent emission of the FITC (l Ex 495 gma n dE m5 2 1gm)
and doxorubicin (l Ex 480 gm and Em 596 gm) was measured by
fluorimeter (Shimadzu FL 2000). Concurrent results of three
independent observations are reported along with standard deviation.
Nanoparticle Recycling Assay
1610
6 SUP-T1 cells were incubated for 30 min in serum free
RPMI medium and FITC labeled apotransferrin nanoparticles were
added to these cells and the incubation was continued for 30 more
minutes. The cells were pelleted by centrifugation at 116 x g for 5
minutes.ThepelletwasextensivelywashedwithPBSandtransferred
to a fresh 12 well plate in 10% serum containing media. The cells
were harvested at different time points and washed thrice with PBS
and lysed in lysis buffer. The lysate was cleared by centrifugation at
11,661 x g for 20 min at 4uC. Fluorescent emissions of both the
FITC (l Ex 495 gm and Em 521 gm) and those of doxorubicin (l
Ex 480 gm and Em 596 gm) were quantified using fluorimetry
(Shimadzu FL 2000). Each of the above experiments was
independently repeated three times to check the reproducibility;
the data is presented in terms of average with standard deviation.
Cellular localization of apotransferrin
One million SUP-T1 cells were incubated for 30 min in serum
free RPMI medium and FITC labeled apotransferrin nanoparti-
cles were added to these cells and the incubation was continued for
30 min, 1–4 hours respectively. After incubation, the cells were
pelleted by centrifugation at 116 x g for 5 minutes. The pellet was
washed thrice with PBS and resuspended in PBC and monitored
on Leica confocal microscope.
MTT assay
This assay was carried out using SUP-T1/Colo-205/SK-N-
SH/PBMCs, as per [54].
Pharmacokinetics and tissue distribution studies
Estimation of doxorubicin in rat blood and tissue samples was
performed as described in [55] with minor modifications as
described below.
Standard solutions of doxorubicin. Doxorubicin hydro-
chloride was used to prepare 1 mg/ml stock standard solution in
methanol. The stock solution was stored at 4uC.
Mobile phase. The buffer, pH 4.0, was prepared from
10 mM ammonium hydrogen phosphate solution, to which
5 mL trimethyl amine was added. The pH of the solution was
adjusted to 4.0 with orthophosphoric acid.
The mobile phase was a mixture of buffer pH 4.0/acetonitrile/
methanol (60:24:16 [V/V/V]), sonicated for 10 min (Biologics
ultrasonic cleaner, India) and filtered through 0.22 mm filter.
Reagents. Aqueous silver nitrate solution (30% m/V) was
prepared by dissolving silver nitrate in purified water. 100 mL
of the reagent was used as protein precipitant. Aqueous
trichloroacetic acid (TCA) (10% m/V) was prepared by
dissolving trichloroacetic acid in purified water. 100 mL of the
reagent was used as protein precipitant. DNA solution (1 mg/mL)
was prepared by dissolving salmon sperm DNA as model DNA
(Hi-Media, India) in purified water. 100 mL of the reagent was
used for the interaction studies.
Instrumentation. The HPLC system (Shimadzu, Japan)
used in this study consists of a Waters 2690 separations module
(comprising a pump, a refrigerated auto sampler with a 20 mL
loop) and a Shimadzu RF-10 AXL fluorescence detector
(Shimadzu Corporation, Japan). The detector was set at 480 nm
and 560 nm (excitation and emission wavelengths, respectively).
The detector was set at gain 3 and sensitivity 1. Chromatographic
separation was performed on a 15064.6 mm i.d. reversed-phase
C18 column. Separation of analytes was performed at a flow rate
of 1.3 mL/min
21, and at a typical back pressure of 12.67 MPa.
Blood samples. Standard solution of doxorubicin
hydrochloride (Doxo) was added to 400 mL rat whole blood
(containing EDTA) in a glass tube in respective amounts to obtain
the final concentrations of 10, 40, 80, 160, 240 and 480 ng/mL of
Doxo. To this mixtures 100 mL of 30% AgNO3 was added. The
contents were vortexed for 1 min and 5 mL methanol was added.
The mixture was extracted for 10 min and centrifuged at 2000
rpm for 10 min at 20uC. The supernatant was decanted into
another glass tube and evaporated to dryness at 60uC under a
stream of nitrogen. The dried residue was reconstituted with
200 mL methanol and centrifuged at 15000 rpm for 10 min. Clear
supernatant was collected in HPLC vials and loaded onto the
HPLC system.
Tissue Samples. Tissues extracts of liver and brain were
prepared in the extraction buffer. 100 mL of 30% AgNO3 was
added to 600 ml of tissue extract. The contents were vortexed for
1 min and 5 mL methanol was added. The mixture was extracted
for 10 min and centrifuged at 2000 rpm for 10 min at 20uC. The
supernatant was decanted into another glass tube and evaporated
to dryness at 60uC under a stream of nitrogen. The dried residue
was reconstituted with 200 ml methanol and centrifuged at 15000
rpm for 10 min. Clear supernatant was collected in HPLC vials
and loaded onto the HPLC system.
Rat Hepatocellular carcinoma model generation
A group of 6 rats was taken for each of the drug concentration
and the experiments were done as per the guidelines approved by
the Animal Ethics Committee, University of Hyderabad. A sample
of 100 million ZH5 cells (Obtained from Centre for cellular and
Molecular Biology, Hyderabad) in 0.5 ml of peritoneal fluid was
taken and injected into intra peritoneal cavity to the 2 month old
Wister rat (120–140 gms). It is known, that the rat develops ascetic
hepatocellular carcinoma symptoms within 4 days and by 7
th day
it will lose the activity and the animal will die during 7–8
th day due
to multiple metastasis and hepatocellular carcinoma [56].
Dosage schedule. The drug was administered at a rate of
one dose per day, for 10 days through intra peritoneal route using
31-gauge insulin syringe (BD biosciences).
Effective dose. 250 mg of protein equivalent- direct-nano
containing 125 mg of doxorubicin. The particles were dispersed in
0.5 ml of PBS and were administered through intra peritoneal
route to the 120–140 g Wister rat.
Sample collection and analysis
Treated as well as untreated rats were anaesthetized and
sacrificed by standard cervical dislocation method, and blood
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biochemical parameters were estimated.
Estimation of biochemical indicators in serum
Estimation of Urea was done by Bertholet method [57],
Creatinine by picrate method [58], Alkaline phosphatase by
PNPP method [59], LDH [60] by the kits supplied by Qualigens
diagnostics, which are manufactured by Sigma diagnostics (India).
Statistical analysis
The above markers were estimated in six individual rats. The
significance was analyzed by Analysis of variance (ANOVA) to test
whether the mean values among the groups were significantly
different Tukey’s honestly significant difference (HSD) test was
carried out for pair wise comparison of mean values of each group.
Pairwise multiple comparison procedure of Holm-Sidak was used
for pair-wise analysis of results of MTT studies and tissue
distribution studies using Sigma Plot v.11.0.
Supporting Information
Figure S1 Infrared spectroscopic analysis of dried sample of
nanoparticle pellet. Nanoparticles were formed as described the
methods. The ether washed nanoparticle pellet was dried and FT
IR spectrum was recorded. The results shown below clearly
indicate the that the nanoparticles do not possess any oil film.
Found at: doi:10.1371/journal.pone.0007240.s001 (3.84 MB
DOC)
Figure S2 Immunochemical analysis of cancer tissue treated
with doxorubicin in nanoformulation. Treated and untreated rats
were anaesthetized and sacrificed by standard cervical dislocation
method, and blood sample was collected by heart puncture
method and liver tissue was collected and the samples were
immediately washed thrice with PBS and kept in 4% Para
formaldehyde solution. These samples were embedded in paraffin
wax and processed for Haematoxylin/eosin staining and the
specimen was photographed and analysed. The results show a
significant efficacy of direct-nano compared to soluble doxorubicin
and soluble mixture of doxorubicin and apotransferrin.
Found at: doi:10.1371/journal.pone.0007240.s002 (0.29 MB
DOC)
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